David H. Ilson, MD, PhD
The treatment of gastric cancer with immunotherapy continues to be an exciting area of investigation, particularly with the PD-1 inhibitors pembrolizumab (Keytruda) and nivolumab (Opdivo).
on Gastrointestinal Cancers, David H. Ilson, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discussed practice-changing trials, the optimal available therapies, and how immunotherapy fits into the future treatment paradigm for gastric cancer.*
OncLive: Please provide an overview of your presentation on gastric cancer.
One of the most important and potentially practice-changing trials [this past year] was determining the optimal adjuvant therapy for resectable gastric cancer.
... to read the full story